Interleukin 23 and Interleukin 17 Evaluation Before and After Methotrexate Treatment of Basal Cell Carcinoma | ||||
| Zagazig University Medical Journal | ||||
| Article 28, Volume 30, Issue 1.2, January and February 2024, Page 233-240 PDF (852.62 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/zumj.2022.123243.2484 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Nelly Said   1; Shrook Khashaba 2; Ahmed Elgarf3; Dina Esmat4; Kamal ElKashishy1
| ||||
| 1Pathology Department, Faculty of Medicine, Zagazig University, Egypt | ||||
| 2Dermatology, Venereology and Andrology Department, faculty of Medicine, Zagazig University | ||||
| 3Dermatology Venereology and Andrology Department, Faculty of Medicine, Zagazig University, Egypt | ||||
| 4Dermatology, Venereology and Andrology, Faculty of Medicine, Zagazig University | ||||
| Abstract | ||||
| Background: Interleukin 23 (IL 23) and Interleukin 17 (IL 17) are two vital cytokines encountered in cutaneous and non-cutaneous immune-mediated inflammatory conditions and also share in cancer development. Basal cell carcinoma (BCC) is a well-known skin tumor with a high incidence and locally invasive effect but rare metastatic potential and a low mortality rate. Aim: To investigate the association of IL 23 and IL 17 in BCC by immunohistochemical evaluation of both. Methods: Based on a study conducted by us, twenty patients with BCC previously treated with intralesional methotrexate were involved in this study. Both interleukins were evaluated in tumor cells and inflammatory cells pre and post treatment, and expression was compared with treatment response. Results: Overexpression of IL 23 and IL 17 was observed in BCC, moreover, both were decreased post treatment with a significant difference (p | ||||
| Keywords | ||||
| basal cell carcinoma; interleukin 17; interleukin 23; methotrexate | ||||
|
Statistics Article View: 160 PDF Download: 71 |
||||
